WNK-IN-11-d3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
WNK-IN-11-d3 

WNK-IN-11 D3 是一种具有口服活性、选择性和强效的 With-No-Lysine (WNK) 激酶抑制剂。WNK-IN-11 D3 有效调节心血管稳态。

WNK-IN-11-d3

WNK-IN-11-d3 Chemical Structure

CAS No. : 2123483-49-6

规格 价格 是否有货
5 mg ￥7500 询问价格 & 货期
10 mg ￥12000 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

WNK-IN-11 D3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11 D3 is effective at regulating cardiovascular homeostasis[1].

IC50 & Target

WNK[1]
体内研究
(In Vivo)

WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability[1].
WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice[1].
WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg[1].
WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague−Dawley rats[1]
Dosage: 1.5 mg/kg
Administration: P.o.
Result: Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability.
Animal Model: FVB mice[1]
Dosage: 30 mg/kg
Administration: P.o.
Result: Showed significant reductions in systolic blood pressure (SBP) vs untreated mice.
Animal Model: FVB mice[1]
Dosage: 0~100 mg/kg
Administration: P.o.
Result: Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg.

分子量

465.41

Formula

C21H18D3Cl2N5OS
CAS 号

2123483-49-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Yamada K, Levell J, Yoon T, et al. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models. J Med Chem. 2017;60(16):7099-7107.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务